Breast Cancer Archives - MPR

Breast Cancer

MPR Weekly Dose Podcast Episode 41

This week on the Pod: The FDA issues guidance for COVID-19 vaccine development; Accuracy in COVID-19 antibody testing; How statins may improve outcomes for hospitalized COVID-19 patients; and in non-COVID-related news there’s a new drug approvals in breast cancer and Dravet syndome.

Trodelvy Now Available for Metastatic Triple-Negative Breast Cancer

Immunomedics announced the availability of Trodelvy™ (sacituzumab govitecan-hziy) for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least 2 prior therapies for metastatic disease. Trodelvy is the first antibody-drug conjugate to get FDA approval for this indication. Trodelvy is administered via intravenous infusion after reconstitution and dilution. Premedication…

Tukysa Approved for Advanced Unresectable or Metastatic HER2-Positive Breast Cancer

The FDA has approved Tukysa (tucatinib; Seattle Genetics), in combination with trastuzumab and capecitabine, for treatment of adult patients with advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer, including patients with brain metastases, who have received 1 or more prior anti-HER2-based regimens in the metastatic setting.